Ceftriaxone Resistance in Klebsiella pneumoniae

Geographic Variation and Resistance Patterns

• In low- and lower-middle-income countries, pooled ceftriaxone resistance in Klebsiella species reaches 77-81% 1, 2
• Africa shows particularly high resistance: 88% (95% CI 72-96%) compared to Asia's 77% (95% CI 65-87%) 1, 2
• These resistance rates make ceftriaxone empirically unreliable in these settings without susceptibility testing 1

Mechanisms of Resistance

• Klebsiella acquires ceftriaxone resistance primarily through extended-spectrum β-lactamases (ESBLs) that hydrolyze the β-lactam ring 3, 4
• ESBL-producing strains typically remain carbapenem-susceptible, though carbapenem resistance is increasing (10% pooled prevalence) 1, 2, 4

Treatment Guidelines

• The Infectious Diseases Society of America recommends carbapenems as first-line for ESBL-producing Klebsiella 4
• For carbapenem-resistant strains, use ceftazidime/avibactam or meropenem/vaborbactam 4
• In high-resistance areas (>25-35% resistance), avoid empiric ceftriaxone 1, 2
• Consider carbapenem empirically in critically ill patients or high-resistance settings 4